{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T08:01:34Z","timestamp":1768723294609,"version":"3.49.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019693","name":"Universidade Federal da Fronteira Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["404256\/2021\\u20130"],"award-info":[{"award-number":["404256\/2021\\u20130"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["310606\/2021\\u20137"],"award-info":[{"award-number":["310606\/2021\\u20137"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bcp.2024.116388","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T15:20:18Z","timestamp":1719069618000},"page":"116388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Takotsubo syndrome as an outcome of the use of checkpoint inhibitor therapy in patients with COVID-19"],"prefix":"10.1016","volume":"226","author":[{"given":"J\u00falia Le\u00e3o Batista","family":"Sim\u00f5es","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge\u00f3rgia de Carvalho","family":"Braga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Victor","family":"Coiado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Bachietti","family":"Scaramussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula Barasuol","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-4980","authenticated-orcid":false,"given":"Margarete Dulce","family":"Bagatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116388_b0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ihj.2017.09.005","article-title":"Takotsubo syndrome","volume":"70","author":"Gupta","year":"2018","journal-title":"Indian Heart J."},{"key":"10.1016\/j.bcp.2024.116388_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.25122\/jml-2018-0067","article-title":"Takotsubo Cardiomyopathy: A Brief Review","volume":"13","author":"Amin","year":"2020","journal-title":"J. Med. Life"},{"key":"10.1016\/j.bcp.2024.116388_b0015","doi-asserted-by":"crossref","unstructured":"Y-Hassan S, Tornvall P. Epidemiology, pathogenesis, and management of takotsubo syndrome. Clinical Autonomic Research 2018; 28: 53.","DOI":"10.1007\/s10286-017-0465-z"},{"key":"10.1016\/j.bcp.2024.116388_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100763","article-title":"Takotsubo Syndrome and COVID-19: Associations and Implications","volume":"46","author":"Shah","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.bcp.2024.116388_b0025","article-title":"Management of Takotsubo Syndrome: A Comprehensive Review","volume":"12","author":"Sattar","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2024.116388_b0030","first-page":"171","article-title":"Takotsubo Cardiomyopathy","volume":"30","author":"Chen","year":"2022","journal-title":"J. Int. Med. Taiwan"},{"key":"10.1016\/j.bcp.2024.116388_b0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/jocs.15251","article-title":"Takotsubo cardiomyopathy caused by emotional stressors in the coronavirus disease 2019 (COVID-19) pandemic era","volume":"36","author":"Kir","year":"2021","journal-title":"J. Card. Surg."},{"key":"10.1016\/j.bcp.2024.116388_b0040","article-title":"A review of the presentation and outcome of takotsubo cardiomyopathy in COVID-19. Monaldi Archives for Chest Disease; 91","author":"John","year":"2021","journal-title":"Epub Ahead of Print"},{"key":"10.1016\/j.bcp.2024.116388_b0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jjcc.2020.10.004","article-title":"Update of Takotsubo syndrome in the era of COVID-19","volume":"77","author":"Okura","year":"2021","journal-title":"J. Cardiol."},{"key":"10.1016\/j.bcp.2024.116388_b0050","doi-asserted-by":"crossref","unstructured":"Dos Anjos F, Sim\u00f5es JLB, Assmann CE, et al. Potential therapeutic role of purinergic receptors in cardiovascular disease mediated by SARS-CoV-2. J Immunol Res; 2020. Epub ahead of print 2020. DOI: 10.1155\/2020\/8632048.","DOI":"10.1155\/2020\/8632048"},{"key":"10.1016\/j.bcp.2024.116388_b0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/abbs\/gmaa176","article-title":"Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment","volume":"53","author":"Luo","year":"2021","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.bcp.2024.116388_b0060","doi-asserted-by":"crossref","unstructured":"Budnik M, Pi\u0105tkowski R, Ochijewicz D, et al. Pathophysiology of Takotsubo Syndrome as A Bridge to Personalized Treatment. J Pers Med; 11. Epub ahead of print 1 September 2021. DOI: 10.3390\/JPM11090879.","DOI":"10.3390\/jpm11090879"},{"key":"10.1016\/j.bcp.2024.116388_b0065","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00059-020-04906-2","article-title":"Takotsubo syndrome: between evidence, myths, and misunderstandings","volume":"45","author":"Napp","year":"2020","journal-title":"Herz"},{"key":"10.1016\/j.bcp.2024.116388_b0070","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2024.116388_b0075","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/heartjnl-2016-309783","article-title":"Takotsubo syndrome: aetiology, presentation and treatment","volume":"103","author":"Kato","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.bcp.2024.116388_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10030479","article-title":"Current Knowledge and Future Challenges in Takotsubo Syndrome: Part 1\u2014Pathophysiology and Diagnosis","volume":"10","author":"Rawish","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2024.116388_b0085","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/cphy.c130051","article-title":"Autonomic Nervous System and Immune System Interactions","volume":"4","author":"Kenney","year":"2014","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.bcp.2024.116388_b0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.0903395","article-title":"Cutting Edge: Sympathetic Nervous System Increases Proinflammatory Cytokines and Exacerbates Influenza A Virus Pathogenesis","volume":"184","author":"Grebe","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbi.2015.01.015","article-title":"Norepinephrine preferentially modulates memory CD8 T cell function inducing inflammatory cytokine production and reducing proliferation in response to activation","volume":"46","author":"Slota","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2024.116388_b0100","doi-asserted-by":"crossref","unstructured":"Hegde S, Khan R, Zordok M, et al. Characteristics and outcome of patients with COVID-19 complicated by Takotsubo cardiomyopathy: case series with literature review. Open Heart; 7. Epub ahead of print 5 October 2020. DOI: 10.1136\/OPENHRT-2020-001360.","DOI":"10.1136\/openhrt-2020-001360"},{"key":"#cr-split#-10.1016\/j.bcp.2024.116388_b0105.1","unstructured":"Anka AU, Tahir MI, Abubakar SD, et al. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol"},{"key":"#cr-split#-10.1016\/j.bcp.2024.116388_b0105.2","doi-asserted-by":"crossref","unstructured":"93. Epub ahead of print 1 April 2021. DOI: 10.1111\/SJI.12998.","DOI":"10.1111\/sji.12998"},{"key":"10.1016\/j.bcp.2024.116388_b0110","doi-asserted-by":"crossref","unstructured":"Ramos SG, Rattis BA da C, Ottaviani G, et al. ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients. Am J Pathol 2021; 191: 1154.","DOI":"10.1016\/j.ajpath.2021.04.010"},{"key":"10.1016\/j.bcp.2024.116388_b0115","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fimmu.2020.01472","article-title":"Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis","volume":"11","author":"Sfera","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/1744666X.2021.1919086","article-title":"The role of IL-6 and IL-6 blockade in COVID-19","volume":"17","author":"Potere","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107225","article-title":"The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease","volume":"90","author":"Pasrija","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116388_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2141","article-title":"Interleukin-6 in Covid-19: A systematic review and meta-analysis","volume":"30","author":"Coomes","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.bcp.2024.116388_b0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2024.116388_b0140","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 Cytokine Storm; What We Know So Far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11739-020-02569-9","article-title":"COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs","volume":"16","author":"Bartoli","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.bcp.2024.116388_b0150","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1253\/circj.CJ-08-0988","article-title":"Upregulation of heme oxygenase-1 in an animal model of Takotsubo cardiomyopathy","volume":"73","author":"Ueyama","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.bcp.2024.116388_b0155","doi-asserted-by":"crossref","unstructured":"Fan X, Yang G, Kowitz J, et al. Takotsubo Syndrome: Translational Implications and Pathomechanisms. Int J Mol Sci; 23. Epub ahead of print 1 February 2022. DOI: 10.3390\/IJMS23041951.","DOI":"10.3390\/ijms23041951"},{"key":"10.1016\/j.bcp.2024.116388_b0160","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Trevi\u00f1o P, Sep\u00falveda-Leal J, Altamirano J. Simultaneous assessment of calcium handling and contractility dynamics in isolated ventricular myocytes of a rat model of post-acute isoproterenol-induced cardiomyopathy. Cell Calcium; 86. Epub ahead of print 1 March 2020. DOI: 10.1016\/J.CECA.2019.102138.","DOI":"10.1016\/j.ceca.2019.102138"},{"key":"10.1016\/j.bcp.2024.116388_b0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1567202617666191223144715","article-title":"Role of PI3K\/AKT\/mTOR Pathway Associated Oxidative Stress and Cardiac Dysfunction in Takotsubo Syndrome","volume":"17","author":"Mao","year":"2020","journal-title":"Curr. Neurovasc. Res."},{"key":"10.1016\/j.bcp.2024.116388_b0170","doi-asserted-by":"crossref","unstructured":"Qi C, Shao Y, Liu X, et al. The cardioprotective effects of icariin on the isoprenaline-induced takotsubo-like rat model: Involvement of reactive oxygen species and the TLR4\/NF-\u03baB signaling pathway. Int Immunopharmacol; 74. Epub ahead of print 1 September 2019. DOI: 10.1016\/J.INTIMP.2019.105733.","DOI":"10.1016\/j.intimp.2019.105733"},{"key":"10.1016\/j.bcp.2024.116388_b0175","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cvr\/cvab081","article-title":"Metabolic alterations in a rat model of Takotsubo syndrome","volume":"118","author":"Godsman","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2024.116388_b0180","doi-asserted-by":"crossref","unstructured":"Qi C, Liu X, Xiong T, et al. Tempol prevents isoprenaline-induced takotsubo syndrome via the reactive oxygen species\/mitochondrial\/anti-apoptosis \/p38 MAPK pathway. Eur J Pharmacol; 886. Epub ahead of print 5 November 2020. DOI: 10.1016\/J.EJPHAR.2020.173439.","DOI":"10.1016\/j.ejphar.2020.173439"},{"key":"10.1016\/j.bcp.2024.116388_b0185","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jmv.26424","article-title":"Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes","volume":"93","author":"Li","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2024.116388_b0190","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.118.037975","article-title":"Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy","volume":"139","author":"Scally","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2024.116388_b0195","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2024.116388_b0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116388_b0205","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12630-016-0680-4","article-title":"Takotsubo cardiomyopathy and its relevance to anesthesiology: a narrative review","volume":"63","author":"Hessel","year":"2016","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.bcp.2024.116388_b0210","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/infdis\/jiab061","article-title":"Increased PD-L1 expression may be associated with the cytokine storm and CD8 + T-cell exhaustion in severe COVID-19","volume":"223","author":"Chen","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2024.116388_b0215","doi-asserted-by":"crossref","unstructured":"Pandolfi L, Fossali T, Frangipane V, et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. BMC Pulm Med; 20. Epub ahead of print 1 December 2020. DOI: 10.1186\/S12890-020-01343-Z.","DOI":"10.1186\/s12890-020-01343-z"},{"key":"10.1016\/j.bcp.2024.116388_b0220","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2024.116388_b0225","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 Axis and Virus Infections: A Delicate Balance","volume":"9","author":"Sch\u00f6nrich","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bcp.2024.116388_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/cells9102206","article-title":"Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils\u2019 but Impaired Monocytes\u2019 and Dendritic Cells\u2019 Responsiveness","volume":"9","author":"Parackova","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2024.116388_b0235","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/infdis\/jiaa591","article-title":"A granulocytic signature identifies COVID-19 and its severity","volume":"222","author":"Vitte","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2024.116388_b0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20139-1","article-title":"Deep RNA sequencing of intensive care unit patients with COVID-19","volume":"12","author":"Fredericks","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116388_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.695242","article-title":"PD-L1 Dysregulation in COVID-19 Patients","volume":"12","author":"Sabbatino","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0250","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2024.116388_b0255","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III Interferons \u2013 Induction, Signaling, Evasion, and Application to Combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bcp.2024.116388_b0260","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1073\/pnas.0809422106","article-title":"PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","volume":"106","author":"Huang","year":"2009","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2024.116388_b0265","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0270","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/2159-8290.CD-20-0596","article-title":"Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers","volume":"10","author":"Luo","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2024.116388_b0275","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(20)30275-7","article-title":"COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study","volume":"2","author":"Manson","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.bcp.2024.116388_b0280","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1080\/09546634.2020.1822500","article-title":"COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma","volume":"33","author":"Arenbergerova","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.bcp.2024.116388_b0285","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2024.116388_b0290","doi-asserted-by":"crossref","unstructured":"Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal; 20. Epub ahead of print 1 December 2022. DOI: 10.1186\/S12964-022-00854-Y.","DOI":"10.1186\/s12964-022-00854-y"},{"key":"10.1016\/j.bcp.2024.116388_b0295","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcp.2024.116388_b0300","doi-asserted-by":"crossref","unstructured":"Wu Q, Qian W, Sun X, et al. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol; 15. Epub ahead of print 1 December 2022. DOI: 10.1186\/S13045-022-01362-9.","DOI":"10.1186\/s13045-022-01362-9"},{"key":"10.1016\/j.bcp.2024.116388_b0305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bcp.2024.116388_b0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116388_b0315","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bcp.2024.116388_b0320","doi-asserted-by":"crossref","unstructured":"Geuijen C, Tacken P, Wang LC, et al. A human CD137\u00d7PD-L1 bispecific antibody promotes antitumor immunity via context-dependent T cell costimulationcostimulation and checkpoint blockade. Nat Commun; 12. Epub ahead of print 1 December 2021. DOI: 10.1038\/S41467-021-24767-5.","DOI":"10.1038\/s41467-021-24767-5"},{"key":"10.1016\/j.bcp.2024.116388_b0325","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2024.116388_b0330","doi-asserted-by":"crossref","unstructured":"Sheng H, Huang Y, Xiao Y, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer; 8. Epub ahead of print 26 May 2020. DOI: 10.1136\/JITC-2019-000340.","DOI":"10.1136\/jitc-2019-000340"},{"key":"10.1016\/j.bcp.2024.116388_b0335","doi-asserted-by":"crossref","unstructured":"Chami P, Diab Y, Khalil DN, et al. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. Int J Mol Sci; 24. Epub ahead of print 1 December 2023. DOI: 10.3390\/IJMS242316773.","DOI":"10.3390\/ijms242316773"},{"key":"10.1016\/j.bcp.2024.116388_b0340","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell costimulationcostimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0345","article-title":"Cardiac Complications in Immune Checkpoint Inhibition Therapy. Front Cardiovasc Med; 6","author":"Tajiri","year":"2019","journal-title":"Epub Ahead of Print"},{"key":"10.1016\/j.bcp.2024.116388_b0350","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bcp.2024.116388_b0355","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.05.026","article-title":"Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019","volume":"135","author":"Di Cosimo","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116388_b0360","doi-asserted-by":"crossref","unstructured":"Onofrio L, Caraglia M, Facchini G, et al. Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Sci OA; 6. Epub ahead of print 1 September 2020. DOI: 10.2144\/FSOA-2020-0091.","DOI":"10.2144\/fsoa-2020-0091"},{"key":"10.1016\/j.bcp.2024.116388_b0365","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2021.03.199","article-title":"Immunotherapy use outside clinical trial populations: never say never?","volume":"32","author":"Rzeniewicz","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2024.116388_b0370","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ejhf.1497","article-title":"Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication","volume":"21","author":"Ederhy","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2024.116388_b0375","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"J. Am. Coll. Cardiol. Img."},{"key":"10.1016\/j.bcp.2024.116388_b0380","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2024.116388_b0385","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2024.116388_b0390","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week","volume":"74","author":"Ball","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2024.116388_b0395","doi-asserted-by":"crossref","first-page":"e16373","DOI":"10.1016\/j.heliyon.2023.e16373","article-title":"Cardiovascular events after the initiation of immune checkpoint inhibitors","volume":"9","author":"Suzuki","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bcp.2024.116388_b0400","doi-asserted-by":"crossref","unstructured":"Trontzas IP, Vathiotis IA, Kyriakoulis KG, et al. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers (Basel); 15. Epub ahead of print 1 May 2023. DOI: 10.3390\/CANCERS15092637.","DOI":"10.3390\/cancers15092637"},{"key":"10.1016\/j.bcp.2024.116388_b0405","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCMA.0000000000000910","article-title":"A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients","volume":"86","author":"Ho","year":"2023","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.bcp.2024.116388_b0410","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2169\/internalmedicine.5317-20","article-title":"The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy","volume":"60","author":"Tsuruda","year":"2021","journal-title":"Intern. Med."},{"key":"10.1016\/j.bcp.2024.116388_b0415","doi-asserted-by":"crossref","first-page":"91","DOI":"10.31662\/jmaj.2021-0001","article-title":"Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events","volume":"4","author":"Kadowaki","year":"2021","journal-title":"JMA J"},{"key":"10.1016\/j.bcp.2024.116388_b0420","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/imm.13262","article-title":"T-cell responses and therapies against SARS-CoV-2 infection","volume":"162","author":"Toor","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2024.116388_b0425","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.121.055854","article-title":"Takotsubo Syndrome: Pathophysiology, Emerging Concepts and Clinical Implications","volume":"145","author":"Singh","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2024.116388_b0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1981","article-title":"Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116388_b0435","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/ehjci\/jeaa178","article-title":"Global evaluation of echocardiography in patients with COVID-19","volume":"21","author":"Dweck","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.bcp.2024.116388_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-00925-8","article-title":"New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity","volume":"22","author":"Khunger","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116388_b0445","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.bcp.2024.116388_b0450","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1097\/CM9.0000000000001090","article-title":"Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective","volume":"133","author":"Shi","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.bcp.2024.116388_b0455","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2024.116388_b0460","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2024.116388_b0465","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19","volume":"23","author":"Majumder","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2024.116388_b0470","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"J. Am. Med. Assoc."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522400371X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522400371X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:12:05Z","timestamp":1728346325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522400371X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":95,"alternative-id":["S000629522400371X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116388","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Takotsubo syndrome as an outcome of the use of checkpoint inhibitor therapy in patients with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116388"}}